Antipicornavirus drugs: Current status

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 5, 1997, Pages 401-408

  Diana, G D ^a   Pevear, D C ^a  

^a ViroPharma Inc   (United States)

Author keywords

Antiviral; Capsid binding; Clinical studies; Enterovirus; Picornavirus

Indexed keywords

4' ETHOXY 2' HYDROXY 4,6' DIMETHOXYCHALCONE; ANTIVIRUS AGENT; BINDING PROTEIN; CAPSID PROTEIN; CHALCONE DERIVATIVE; ENVIROXIME; INTERCELLULAR ADHESION MOLECULE 1; PIRODAVIR; PLECONARIL; SCH 48973; SDZ 35682; UNCLASSIFIED DRUG; ZINC DERIVATIVE;

ANTIVIRAL ACTIVITY; COXSACKIE VIRUS; CRYSTAL STRUCTURE; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; PICORNAVIRUS; PRIORITY JOURNAL; REVIEW; RHINOVIRUS; VIRUS MORPHOLOGY;

EID: 0030930543     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800502     Document Type: Review

References (73)

1. Abraham G & Colonno RT (1984) Many rhinovirus serotypes share the same cellular receptor. Journal of Virology 51: 340-345.
2. Al-Nakib W, Higgins P, Barrow I, Tyrell DAJ, Lenox-Smith I & Ishitsuka H (1987a) Intranasal chalcone Ro 0410, as prophylaxis against rhinovirus infections in human volunteers. Journal of Antimicrobial Chemotherapy 20: 887-892.
3. Al-Nakib W, Higgins PG, Barrow I, Balstone G & Tyrell DA (1987b) Prophylaxis and treatment of rhinovirus colds with zinc gluconate. Antimicrobial Agents and Chemotherapy 20: 893-901.
4. Al-Nakib W, Higgins PG, Barrow GI, Tyrell DAJ, Andries K, Vanden Bussche G, Taylor N & Janssen P (1989) Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug. Antimicrobial Agents and Chemotherapy 33: 522-525.
5. Andries K, Dewindt B, Snoeks J, Willebrords K, Van Eemeren K & Stokbroekx K (1991) Antirhinovirus spectrum and mechanism of action of R77975. Antiviral Research 15 (Supplement 1): Abstract 101.
6. Andries K, Stokbroekx R, Dewindt B & Snoeks J (1992) In vitro activity of pirodavir (R77975), a substituted phenoxy-pyridazinamine with broad spectrum antipicornaviral activity. Antimicrobial Agents and Chemotherapy 36: 100-107.
7. Arruda E, Crump CE, Martin SD, Merluzzi VJ & Hayden FG (1992) In vitro studies of the antirhinovirus activity of soluble intercellular adhesion molecule-1. Antimicrobial Agents and Chemotherapy 36: 1186-1191.
8. Arruda E, Crump CE & Hayden FG (1994) In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1. Antimicrobial Agents and Chemotherapy 38: 66-70.
9. Bibler-Muckelbauer JK, Kremer MJ, Rossmann MG, Diana GD, Dutko FJ, Pevear DC & McKinlay MA (1994) Human rhinovirus 14 complexed with fragments of antiviral compounds. Virology 202: 360-369.
10. Buontempo P, Wright-Minogue J, Cox S, DeMartino J, Girijavallablan V, Rozhon E, Schwartz J & O'Connell J (1995) Mechanism of action of SCH 47802: an antipicornavirus molecule. Antiviral Research 26 (Supplement 3): A346.
11. Chandra RK (1984) Excessive intake of zinc impairs immune responses. Journal of the American Medical Association 252: 1143-1145.
12. Chapman MS, Minor I, Rossmann MG, Diana GD & Andries K (1991) Human rhinovirus 14 complexed with antiviral compound R 61837. Journal of Molecular Biology 217: 455-463.
13. Cox S, Buontempo J, Wright-Minogue J, Skelton A, DeMartino J, Roshon E, Linn C, Girijavallablan V, Schwartz J & O'Connell J (1995) Antipicornavirus activity of SCH 47802: in vitro and in vivo studies. Antiviral Research 26 (Supplement 3): A345.
14. Cox S, Buontempo PJ, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Schwartz J, Rozhon EJ, Linn C, Girijavallablan V & O'Connell J (1996) Antipicornavirus activity of SCH 47802 and analogues: in vitro and in vivo studies. Antiviral Research 32: 71-79.
15. Crump CE, Arruda E & Hayden FG (1993) In vitro inhibitory activity of soluble ICAM-1 for the numbered serotypes of human rhinovirus. Antiviral Chemistry and Chemotherapy 4: 323-327.
16. Dearden C, Al-Nakib W, Andries K, Woestenborghs R & Tyrell DAJ (1989) Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Archives of Virology 109: 71-81.
17. Diana GD, Volkots DL, Nitz TJ, Bailey TR, Long MA, Vescio N, Aldous S, Pevear DC & Dutko FJ (1994) Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. Journal of Medicinal Chemistry 37: 2421-2436.
18. Diana GD, Rudewicz P, Pevear DC, Nitz TJ, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FT, Aldi C, Gendron G, Oglesby RC, Volkots DL, Reuman M, Bailey TR, Czerniak R, Block T, Roland R & Oppermann J (1995) Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. Journal of Medicinal Chemistry 38: 1355-1371.
19. Douglas RM, Miles HB, Moore BW, Ryan P & Pinnock CB (1987) Failure of effervescent zinc acetate lozenges to alter the course of upper respiratory tract infections in Australian adults. Antimicrobial Agents and Chemotherapy 31: 1263-1265.
20. Dustin ML & Springer TA (1988) Lymphocyte function associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. Journal of Cell Biology 107: 321-331.
21. Eby GA, Davis DR & Halcomb WW (1984) Reduction in duration in common colds by zinc gluconate lozenges in a double-blind study. Antimicrobial Agents and Chemotherapy 25: 20-24.
22. Farr BM & Gwaltney Jr JM (1987) The problems of taste in placebo matching an evaluation of zinc gluconate for the common cold. Journal of Chronic Diseases 40: 875-879.
23. Farr BM, Conner EM, Betts RF, Oleske J, Minnifer A & Gwaltney Jr JM (1987) Two randomized controlled trials of zinc gluconate lozenge therapy of experimentally induced rhinovirus colds. Antimicrobial Agents and Chemotherapy 8: 1183-1187.
24. Geist FC, Bateman JA & Hayden FG (1987) In vitro activity of zinc salts against human rhinovirus. Antimicrobial Agents and Chemotherapy 31: 622-624.
25. Giranda VL, Chapman MS & Rossmann MG (1990) Modeling of the human intercellular adhesion molecule-1, the human rhinovirus major group receptor. Proteins 7: 227-233.
26. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, Kamarck ME & McClelland A (1989) The major rhinovirus receptor is ICAM-1. Cell 56: 849-853.
27. Greve JM, Fortes CP, Marlor CW, Meyer AM, Hoover-Litty H, Wunderlich D & McClelland A (1991) Mechanism of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. Journal of Virology 65: 6015-6023.
28. Hayden FG & Gwaltney Jr JM (1982) Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrobial Agents and Chemotherapy 21: 892-897.
29. Hayden FG, Andries K & Janssen PA (1992) Safety and efficacy of intranasal pirodavir (R 77975) in experimental rhinovirus infection. Antimicrobial Agents and Chemotherapy 36: 727-732.
30. Hayden FG, Eisen G, Janssen M, Andries K & Janssen P (1993) Safety and efficacy of intranasal pirodavir (R 77975) for treatment of naturally occurring common colds. Antimicrobial Agents and Chemotherapy 36: 727-732.
31. Heinz BA & Vance LM (1995) The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. Journal of Virology 69: 4189-4197.
32. Higgins PG, Barrow GI & Tyrell DAJ (1990) A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers. Antiviral Research 14: 339-344.
33. Hofer F, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E & Blaas D (1994) Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proceedings of the National Academy of Sciences, USA 91: 1839-1842.
34. Ishitsuka H, Ninomiya YT, Ohsawa C, Fujiu M & Suhara Y (1982a) Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrobial Agents and Chemotherapy 22: 617-621.
35. Ishitsuka H, Ohsawa C, Ohiva T, Umeda I & Suhara Y (1982b) Antipicornavirus flavone Ro-09-0179. Antimicrobial Agents and Chemotherapy 22: 611-616.
36. Kaplan G, Peters D & Racaniello VR (1990) Poliovirus mutants resistant to neutralization with soluble cell receptors. Science 250: 1596-1599.
37. Kim S, Smith TJ, Chapman MS, Rossmann MG, Pevear DC, Dutko FJ, Felock PT, Diana GD & McKinlay MA (1989) Crystal structure of human rhinovirus serotype 1A (HRV 1A). Journal of Molecular Biology 210: 91-111.
38. Kim S, Willingmann P, Gong ZX, Kremer MJ, Chapman MS, Minor I, Oliviera MA, Rossmann MG, Andries K, Diana GD, Dutko FJ, McKinlay MA & Pevear DC (1993) A comparison of the antirhinoviral drug binding pocket in HRV 14 and HRV 1A. Journal of Molecular Biology 230: 206-227.
39. Korant BD & Butterworth BE (1976) Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides. Journal of Virology 18: 298-306.
40. Lonberg-Holm K & Korant BD (1972) Early interaction of rhinoviruses with host cells. Journal of Virology 9: 29-49.
41. Madshus IH, Olsnes S & Sandvig K (1984) Different pH requirements for entry of the two picornaviruses, human rhinovirus 2 and murine encephalomyocarditis virus. Virology 139: 346-357.
42. Mallamo JP, Diana GD, Pevear DC, Dutko FJ, Chapman MS, Kim KH, Minor I, Oliviera M & Rossmann MG (1992) Conformationally restricted analogues of disoxaril: a comparison of the activities against human rhinovirus types 14 and 1A. Journal of Medicinal Chemistry 35: 4690-4695.
43. Martin SD, Staunton DE, Springer TA, Stratowa C, Sommergruber W & Merluzzi VJ (1990) A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 344: 70-72.
44. Martin S, Casanovas JM, Staunton DE & Springer TA (1993) Successful prevention of rhinovirus infections with chimeric ICAM-1 immunoglobulin in vitro. Medizinishe Klinik 88: 193-197.
45. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER & Srivastava S (1985) Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrobial Agents and Chemotherapy 27: 102-106.
46. Monto AS, Schwartz SA & Albrecht JK (1989) Ineffectiveness of post exposure prophylaxis of rhinovirus infection with low-dose intranasal alpha interferon in families. Antimicrobial Agents and Chemotherapy 33: 387-390.
47. Muckelbauer JK, Kremer M, Minor I, Diana G, Dutko FJ, Groarke J, Pevear DC & Rossmann MG (1995) The structure of coxsackievirus B3 at 3.5Å resolution. Structure 3: 653-667.
48. Neubauer C, Frasel L, Kuechler E & Blaas D (1987) Mechanism of entry of human rhinovirus 2 into HeLa cells. Virology 158: 255-258.
49. Ninomiya Y, Ohasawa C, Aoyama M, Umeda I, Suhara Y & Ishitsuka H (1984) Antivirus agent Ro 09-0410 binds to rhinovirus specifically and stabilizes the virus conformation. Virology 134: 269-276.
50. Ninomiya Y, Aoyama M, Umeda I, Suhara Y & Ishitsuka H (1985) Comparative studies on the modes of action of the antirhinovirus agent Ro 09-0410, Ro 09-0179, RMI-15,731, 4′6-dichloroflavin and enviroxime. Antimicrobial Agents and Chemotherapy 27: 595-599.
51. Ninomiya Y, Shimma N & Ishitsuka H (1990) Comparative studies on the antirhinovirus activity and mode of action of the rhinovirus capsid binding agents, chalcone amides. Antiviral Research 13: 61-64.
52. Novick SG, Godfroy JC, Godfroy NJ & Wilder HR (1996) How does zinc modify the common cold? Clinical observation and implications regarding mechanisms of action. Medical Hypothesis 46: 295-302.
53. Ohlin A, Hoover-Litty H, Sanderson G, Paessens A, Johnston SL, Holgate ST, Huguenel E & Greve JM (1994) Spectrum of activity of intercellular adhesion molecule-1 against rhinovirus reference strains and field isolates. Antimicrobial Agents and Chemotherapy 38: 1413-1415.
54. Oliviera MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, Pevear DC, Dutko FJ, McKinlay MA & Rossmann MG (1993) The structure of human rhinovirus 16. Structure 1: 51-68.
55. Olson NH, Kolatkar PR & Oliviera MA (1993) Structure of the human rhinovirus complexed with its receptor molecule. Proceedings of the National Academy of Sciences, USA 90: 507-511.
56. Phillpotts RJ, Wallace J, Tyrell DAJ & Tagart VB (1983) Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrobial Agents and Chemotherapy 23: 671-675.
57. Phillpotts RJ, Higgins PG, Willman JS, Tyrell DJA & Lenox-Smith I (1984) Evaluation of antirhinovirus chalcone Ro 09-0415 given orally to volunteers. Antimicrobial Agents and Chemotherapy 14: 403-409.
58. Rosenwirth B, Kis ZL & Eggers HJ (1995) In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent. Antiviral Research 26: 55-64.
59. Rossmann MG & Palmenberg AC (1988) Conservation of the putative receptor attachment site in picornaviruses. Virology 164: 373-382.
60. Rossmann MG, Arnold E, Erickson JW, Frankinberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG, Rueckert RR, Sherry B & Vriend G (1985) Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317: 145-153.
61. Rozhon E, Cox S, Buontempo P, O'Connell J, Slater W, DeMartino J, Schwartz J, Miller G, Arnold E, Zhang A, Morrow C, Jablonski S, Pinto P, Versace R, Duelfer T & Girijavallabhan V (1993) SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Research 21: 15-35.
62. Rueckert RR (1987) Picornaviridae: the viruses and their replication. In Fields Virology, 2nd edn. Edited by BN Fields & DM Knipe. New York: Lippincott Raven, pp. 507-508.
63. Schiff GM, Sherwood JR, Young EC, Mason LJ & Gamble JN (1992) Prophylactic efficacy of WIN 54954 in prevention of experimental human coxsackie A21 infection and illness. Antiviral Research 17 (Supplement 1): 92.
64. Shepard DA, Heinz BA & Rueckert RR (1993) Win 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. Journal of Virology 67: 2245-2254.
65. Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, Rossmann MG, McKinlay MA, Diana GD & Otto MJ (1986) The site of attachment in human rhinovirus 14 of antiviral agents that inhibit uncoating. Science 233: 1286-1293.
66. Sperber SJ & Hayden FG (1988) Chemotherapy of rhinovirus colds. Antimicrobial Agents and Chemotherapy 32: 409-419.
67. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Martin SD & Springer TA (1989) A cell adhesion molecule, ICAM-1 is the major surface receptor for rhinoviruses. Cell 56: 849-853.
68. Tomassini JE, Graham CM, De Witt CM, Linenberger DW, Rodkey JA & Colonno RJ (1989) cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proceedings of the National Academy of Sciences, USA 86: 4907-4911.
69. Turner RB & Hayden FG (1992) Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirus infections. Antiviral Research 17 (Supplement 1): 92.
70. Turner RB, Durean JF, Albrecht JK & Crandall AS (1989) Safety and tolerance of ocular admission of recombinant alpha interferon. Antimicrobial Agents and Chemotherapy 33: 396-397.
71. Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CYE, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND & Chamberlin JW (1980) Synthesis of syn and anti isomers of 6-[(hydroxyimino)phenyl]-1-[(1-methyl)sulfonyl]-1H-benzimidazole-2-amine. Inhibitors of rhinovirus multiplication. Journal of Medicinal Chemistry 23: 368-372.
72. Zhang A, Nanni RG, Oren DAA, Rozhon EJ & Arnold E (1992) Three dimensional structure-relationship for antiviral agents that interact with picornavirus capsid. Seminars in Virology 3: 453-471.
73. Zhao R, Pevear DC, Kremer M, Giranda VL, Kofron JA, Kuhn RJ & Rossmann MG (1996) Human rhinovirus 3 at 3.0 Å resolution. Structure 4: 1205-1220.